Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab

Clinical Cancer Research

Volumn 22, Issue 22, 2016, Pages 5487-5496

  Weide, Benjamin ^a,b   Martens, Alexander ^a   Hassel, Jessica C ^c,d   Berking, Carola ^d,e   Postow, Michael A ^f,g   Bisschop, Kees ^h   Simeone, Ester ⁱ   Mangana, Johanna ^j   Schilling, Bastian ^d,k   Di Giacomo, Anna Maria ^l   Brenner, Nicole ^m   Kähler, Katharina ⁿ   Heinzerling, Lucie ^o   Gutzmer, Ralf ^p   Bender, Armin ^q   Gebhardt, Christoffer ^d,r   Romano, Emanuela ^s   Meier, Friedegund ^d,t   Martus, Peter ^b   Maio, Michele ^l   Blank, Christian ^u   Schadendorf, Dirk ^d,k   Dummer, Reinhard ^j   Ascierto, Paolo A ⁱ   Hospers, Geke ^h   Garbe, Claus ^a,d   Wolchok, Jedd D ^f,g   more..

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j UNIVERSITY OF ZURICH   (Switzerland)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l UNIVERSITY HOSPITAL OF SIENA   (Italy)

^m UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^p HANNOVER MEDICAL SCHOOL   (Germany)

^q UNIVERSITY HOSPITAL MARBURG   (Germany)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s INSTITUT CURIE   (France)

^t UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^u NETHERLANDS CANCER INSTITUTE   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; LACTATE DEHYDROGENASE; PEMBROLIZUMAB; TUMOR MARKER; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; EOSINOPHIL COUNT; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR GROWTH; VISCERAL METASTASIS; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PROGNOSIS; SKIN TUMOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS, TUMOR; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84991541126     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0127     Document Type: Article

References (40)

1. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
2. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
3. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl JMed 2015;372:2521-32.
4. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384: 1109-17.
5. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 2015;16:908-18.
6. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
7. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (Check Mate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16: 375-84.
8. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
9. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064-74.
10. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
11. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013;31: 4311-8.
12. Kefford R, Ribas A, Hamid O, Robert C, Daud A, Wolchok JD, et al. Clinical efficacy and correlationwith tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK- 3475. J Clin Oncol 32:5s, 2014 (suppl; abstr 3005).
13. Daud AI, Hamid O, Ribas A, Hodi FS, Hwu W-J, Kefford R, et al. Abstract CT104: antitumor activity of the anti-PD-1 monoclonal antibody MK- 3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome. Cancer Res 2014;74:CT104.
14. Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 2015;28:245-53.
15. Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment inmetastatic melanoma. Cancer Immunol Immunother 2014;63:449-58.
16. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastaticmelanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013;24: 1697-703.
17. Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. J Clin Oncol 31, 2013 (suppl; abstr 3003).
18. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
19. Chen PL, Roh W, Reuben A, Spencer CNJ, Lazar A, Davies MM, et al. Society for Melanoma Research 2015 Congress. Pigment Cell Melanoma Res 2015;28:763.
20. Vilain RE, Kakavand H, Menzies AM, Madore J, Wilmott J, Dobney R, et al. 3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate. Eur J Cancer 2015;51:S666.
21. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
23. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
24. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
25. Martens A, Wistuba-Hamprecht K, Geukes Foppen MH, Yuan J, Postow MA, Wong P, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treatedwith ipilimumab. Clin Cancer Res. 2016 Jan 19. [Epub ahead of print].
26. Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br J Cancer 2016;114:256-61.
27. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
28. Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol 2012;30:1835-41.
29. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-9.
30. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. Arheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013;14:1212-8.
31. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
32. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
33. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99: 12293-7.
34. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
35. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
36. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007;178: 4222-9.
37. Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol 2012;188:703-13.
38. Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 2015;16: 609-17.
39. Schindler K, Harmankaya K, Postow MA, Frantal S, Bello D, Ariyan CE, et al. Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody. J Clin Oncol 31, 2013 (suppl; abstr 9024).
40. Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 2015;21:5453-9.